Flagship Biosciences is a CAP-accredited and CLIA-certified computational pathology company combining traditional histopathology with artificial intelligence to transform tissue biology into actionable data. We make existing tissue-based assays more powerful as predictive diagnostics by adding significantly more image analysis data from our cTA™ (Computational Tissue Analysis) platform. We deliver scorecards, showcasing endpoints as custom derived biofeatures in the context of tissue biopsies.
ACT Genomics is an innovation–driven cancer solution provider in Asia with offices and laboratories in Taipei, Hong Kong & Tokyo. Through Next-Generation Sequencing (NGS) technology, we provide optimal cancer treatment planning, cancer relapse and drug resistance monitoring, cancer risk assessment and immunotherapy evaluation to medical professionals. Pharmaceutical communities also benefit from our services in identifying biomarkers for drug development, stratifying patients for clinical studies and assessing drug responses.
Myriad RBM, Inc is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
PreAnalytiX, a joint venture between BD and QIAGEN, develops, manufactures and sells integrated and standardized systems for sample collection, stabilization and purification of high-quality RNA, microRNA and DNA from human blood, bone marrow, or tissue specimens. The Company serves healthcare institutions, academic researchers, clinical laboratories and the pharmaceutical industry with a broad array of manual and automated products.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenomic biomarkers for use within the pharmaceutical and biotechnology industries. The Company’s award-winning technology platform, EpiSwitch™, is designed to enable precision medicine programs by providing insights into disease mechanisms in early drug discovery, informing patient selection in clinical trials, and supporting product repositioning approaches. Oxford BioDynamics is headquartered in the UK and listed on the London Stock Exchange’s AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
For nearly 20 years, Ambry has been seeking to better understanding gene-disease relationships through collaboration, research, and innovation. We have identified novel genes, designed custom assays, and brought to market more than 500 unique diagnostic tests. We’ve been first-to-market with game-changing technologies, including clinical exome and hereditary cancer panels. With our committed team of experts, we are equipped with powerful technologies and stand by ready to develop custom assays to meet your specific criteria.
Invivoscribe® is a comprehensive CDx partner, providing ISO13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. We offer internationally standardized testing through our ISO15189 laboratory network (US, Europe, Asia). Our Streamlined CDx™ approach has proven successful in approval of the first-ever AML companion diagnostic – The LeukoStrat® CDx FLT3 Mutation Assay, helping pharmaceutical companies accelerate FDA and PMDA approvals of new targeted therapies for the most deadly form of leukemia.
BioFluidica is a biotechnology company that has developed a diagnostic platform allowing for disease management and diagnosis through prognosis, all from a simple blood test. Biofluidica’s diagnostic platform can precisely capture and isolate disease biomarkers, such as Circulating Tumor Cells and has been clinically validated. Our ability to scan blood for the first signs of a disease means fulfilling the promise of a true liquid biopsy. We are revolutionizing disease diagnostics by improving diagnostics to millions of people.
Cureline, Inc is a global commercial biobank and human biospecimen CRO providing for 15 years effective solutions to biopharmaceutical and academic researchers. We maintain an extensive biorepository of human biospecimens in San Francisco Bay area. Our clinical network expands to over 16 countries and 100 clinical sites.
Viracor Eurofins BioPharma Services helps you advance clinical trials through trusted partnership, excellence in science and exceptional service. We customize assays to meet your study’s needs for phase I-IV trials, through our specialized testing and expertise in complex assay design/transfer, optimization and validation. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing. For additional information, visit Viracor-Eurofins.com.
Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The Singulex Clarity system and Singulex Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting.
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. Asuragen co-develops diagnostic tests with diagnostic and pharmaceutical partners on projects ranging from custom manufactured components to companion diagnostic tests.
Instant NanoBiosensors was founded in 2016 and based in Taiwan.
We focus on biomedical research and medical diagnostics and developed Fiber Optic Particle Plasmon Resonance (FO-PPR) technology, which offers simple, instant and accurate results for a wide range of detection applications.
Combining novel biomarkers with patented FO-PPR technology, our Point-Of-Care Testing (POCT) platform aspire to revolutionize traditional immunoassays because rapid and precise diagnostic make crucial differences by saving time, cost, and lives.
NeoGenomics specializes in cancer genetics testing and information services with the most comprehensive oncology-focused testing menus globally to diagnose and treat cancer. NeoGenomics operates CLIA certified laboratories serving the needs of pathologists, oncologists, academic centers, hospital systems, Pharma, and managed care organizations. Visit http://neogenomics.com/ to learn more about our global locations.?
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way we diagnose and treat diseases such as cancer, autoimmune conditions, and infectious diseases. For more information, please visit adaptivebiotech.com.
Lexogen is a transcriptomics and next-generation sequencing company, focusing on the development of technologies for complete transcriptome sequencing. Their portfolio includes innovative molecular biology kits, software, and services for RNA sequencing. Lexogen headquarters is based in Vienna, Austria and the North American subsidiary in New Hampshire, USA.
CareDx, Inc., based out of Brisbane, California, is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high-quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
DNAnexus has built the world’s most secure cloud platform and global network for scientific collaboration and accelerated discovery. We embrace challenges and partnership to tackle the world’s most exciting opportunities across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, medical centers, government, and research consortia.
PrecisionMed, Inc. is a leading supplier of high quality, accurately annotated human biological material and the largest private global source of longitudinally collected human cerebral spinal fluid from diseased populations and TruNormal® controls. We also provide banked liquid biopsy samples, banked FFPE tissue, as well as prospective collections in all diseases. All of our samples are collected in the United States under U.S. IRB approved clinical protocols.
Pacific Biomarkers maintains a “fit-for-purpose” assay development and validation philosophy that spans feasibility to full validations using CAP, CSLI or FDA bioanalytical guidelines to match the intended use of a sponsor’s drug in development. Our validation work includes all novel biomarkers, technology transfers and bioanalytical work associated with a biologic drug where PK, ADA, and immunogenicity assays are required.